Compare AbbVie Inc (ABBV) vs Cloudflare Inc (NET) Price & Performance

ABBV trades at $249.94, up 1.59% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats (Q4 2025 to Q2 2026) and a 70.73% buy rating from analysts highlight confidence. Revenue grew to $61.16B in 2025, though net margin dipped to 6.9%, while Skyrizi and Rinvoq drive growth post-Humira patent expiry. A dividend of $1.73 is scheduled for August 2026, supporting income appeal.

Outlook is positive with a $281.33 price target, but risks include high P/E of 70.05, patent cliffs in the 2030s, and regulatory lawsuits. Institutional buying and robust pipeline innovations like ELAHERE® in ovarian cancer offer upside, yet valuation and competitive pressures warrant caution for growth sustainability.

Cloudflare (NET) trades at $300.27, up 5.57% on strong Q2 2026 earnings that beat estimates with 36% revenue growth to $696.1 million. The stock shows bullish technical momentum above key support levels, supported by accelerating AI-driven demand and expanding large customer adoption. Recent FedRAMP High authorization enhances government contract opportunities, while the company maintains robust gross margins of 72.58% despite negative net income margins.

Outlook remains positive with analyst consensus targeting $337.10 (12.3% upside), though high valuation multiples (P/S 42.05) and persistent net losses pose risks. The convertible note offering adds financial flexibility but increases leverage. AI infrastructure demand and market share gains provide growth catalysts, but competitive pressures and execution risks require monitoring.